# US 12,215,129 B2 · Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,215,129 B2 - Document ID: US12215129B2 - Status: Granted - Kind: B2 - Application number: 18/034,670 - Filed: 2021-10-29 - Published: 2023-12-07 - Granted: 2025-02-04 - Earliest claimed: 2020-10-30 - Assignees: University of Utah Research Foundation - Applicants: University of Utah Research Foundation - Inventors: Eric W. Schmidt; Margo Haygood; Bailey Miller - Web page: https://patentgrep.com/patent/US12215129B2 ## CPC - C07K 11/02: cyclic, e.g. valinomycins {; Derivatives thereof} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 31/04: Antibacterial agents - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract In one aspect, the invention relates to cyclopeptides and methods of using the disclosed cyclopeptides to treat bacterial infections due to, for example, Gram-negative pathogens. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. ## Claims ### Claim 1 A compound having a structure represented by a formula: wherein R1 is selected from C1-C24 alkyl and C2-C24 alkenyl wherein each of R2, R6, and R9 is independently a side chain of a D-amino acid residue; wherein R3 is a polar uncharged side chain of an amino acid residue; wherein R4 is a hydrophobic side chain of an amino acid residue; wherein R5 is a side chain of an amino acid residue selected from cysteine, selenocysteine, glycine, and proline; wherein R7 is a side chain of a homo-amino acid residue selected from homoserine, homothreonine, homoasparagine, and homoglutamine; wherein R8 is a hydrophobic side chain of an amino acid residue; wherein R10 is an electrically charged side chain of an amino acid residue; wherein each of R11a and R11b is independently selected from hydrogen and C1-C4 alkyl; and wherein each of R12, R13, and R14 is independently selected from —OH, —SH, and —NH2, or a pharmaceutically acceptable salt thereof, provided that the compound does not have a structure represented by a formula: wherein R4 is valine, R6 is D-alloisoleucine, R8 is alanine, R11a is methyl, R11b is hydrogen, and R14 is —OH. ### Claim 2 (depends on 1) The compound of claim 1, wherein R1 is selected from: ### Claim 3 (depends on 1) The compound of claim 1, wherein each of R2, R6, and R9 is independently a side chain of a D-amino acid residue selected from D-lysine, D-threonine, D-phenylalanine, D-methionine, D-histidine, D-tryptophan, D-glutamine, D-aspartate, D-glutamate, D-arginine, D-alanine, D-proline, D-cysteine, D-asparagine, D-serine, D-tyrosine, D-ornithine, D-hydroxybutanoic acid, and D-alloisoleucine. ### Claim 4 (depends on 1) The compound of claim 1, wherein R3 is a polar uncharged side chain of an amino acid residue selected from serine, threonine, asparagine, and glutamine. ### Claim 5 (depends on 1) The compound of claim 1, wherein R4 is a hydrophobic side chain of an amino acid residue selected from alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, and valine. ### Claim 6 (depends on 1) The compound of claim 1, wherein R8 is a hydrophobic side chain of an amino acid residue selected from alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, and valine. ### Claim 7 (depends on 1) The compound of claim 1, wherein R9 is a side chain of an amino acid residue selected from D-alloisoleucine residue and D-valine. ### Claim 8 (depends on 1) The compound of claim 1, wherein R10 is an electrically charged side chain of an amino acid residue selected from arginine, histidine, lysine, aspartic acid, and glutamic acid. ### Claim 9 (depends on 1) The compound of claim 1, wherein R11a is C1-C4 alkyl and R11b is hydrogen. ### Claim 10 (depends on 1) The compound of claim 1, wherein each of R12, R13, and R14 is —OH. ### Claim 11 (depends on 1) The compound of claim 1, wherein the compound has a structure represented by a formula: ### Claim 12 (depends on 1) The compound of claim 1, wherein the compound has a structure represented by a formula: ### Claim 13 (depends on 1) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, and a pharmaceutically acceptable carrier. ### Claim 14 (depends on 1) The compound of claim 1, wherein R1 is selected from C8-C18 alkyl and C8-C18 alkenyl. ### Claim 15 (depends on 1) The compound of claim 1, wherein R2 is D-ornithine. ### Claim 16 (depends on 1) The compound of claim 1, wherein R3 is serine, R4 is valine, and R5 is glycine. ### Claim 17 (depends on 1) The compound of claim 1, wherein R6 is D-alloisoleucine. ### Claim 18 (depends on 1) The compound of claim 1, wherein R7 is homoserine. ### Claim 19 (depends on 1) The compound of claim 1, wherein R8 is alanine. ### Claim 20 (depends on 1) The compound of claim 1, wherein R10 is glutamic acid.